Cancers 2022 April 16 [Link] Tugce Kutuk, Haley Appel, Maria Carolina Avendano, Federico Albrecht, Paul Kaywin, Suyen Ramos, Melanie E Suarez-Murias, Minesh P Mehta, Rupesh Kotecha Abstract Purpose: The objectives of this study were to evaluate the implementation, device usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields and pemetrexed plus platinum-based chemotherapy in…

Read More

The European Respiratory Journal 2017 December 21 [Link] Lamote K, Vynck M, Thas O, Van Cleemput J, Nackaerts K, van Meerbeeck JP Abstract Malignant pleural mesothelioma (MPM) is predominantly caused by asbestos exposure and has a poor prognosis. Breath contains volatile organic compounds (VOCs) and can be explored as an early detection tool. Previously, we…

Read More

Cancers 2017 September [Link] Klampatsa A, Haas AR, Moon EK, Albelda SM Abstract Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs…

Read More

European Journal of Medicinal Chemistry 2017 August [Epub ahead of print] [Link] Facchetti G, Petrella F, Spaggiari L, Rimoldi I Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. Platinum-based chemotherapy in…

Read More

Translational Lung Cancer Research 2017 June [Link] Chan WH, Sugarbaker DJ, Burt BM Abstract Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common. Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic…

Read More

Translational Lung Cancer Research 2017 June [Link] Mancuso MR, Neal JW Abstract Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum…

Read More

Stem cell research & therapy 2017 May 25 [Link] Pattarozzi A, Carra E, Favoni RE, W├╝rth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A Abstract BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after…

Read More